CHMP recommends conditional approval for Genmab and Abbvie's epcoritamab
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a conditional marketing authorization for Genmab and AbbVie’s epcoritamab, a subcutaneous T-cell targeting bispecific antibody, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.